Roche to Develop Diagnostic Test for Cardiovascular Disease - Analyst Blog
Roche Holding Ag RHHBY announced that it has entered into an agreement to develop a companion diagnostic (CDx) test for DalCor Pharmaceuticals’ dalcetrapib.
Dalcetrapib targets patients with a specific genotype who have experienced a recent acute coronary syndrome event.
Roche’s CDx test from will be used in a phase III clinical trial on dalcetrapib. The trial will validate the clinical efficacy of the candidate.
Per a recently published analysis by the Montreal Heart Institute, the candidate could potentially reduce cardiovascular morbidity and mortality by as much as 39% in patients with a specific genetic profile.
Roche specializes in developing drugs for oncology, immunology and infectious diseases. Apart from providing therapeutic products and services for diverse medical needs, the company focuses on innovative diagnostic solutions for the early detection and treatment of diseases.
This pharmaceutical major has a broad portfolio of diagnostic tests with over 100 high-quality Elecsys assays for immune testing, along with a new generation of fully-automated cobas analyzers for improved medical decision making, scheduling and efficiency.
We note that Roche works hard on forming partnerships and developing diagnostic tests. The collaboration with DalCor will allow the company to enter the cardiovascular market and leverage its expertise in developing FDA-approved CDx tests.
In Apr 2015, Roche announced that its member company, Ventana Medical Systems, Inc., has entered into a master collaboration agreement with Japan-based Astellas Pharma Inc. ALPMY to develop novel automated tissue diagnostics.
We are impressed by Roche’s efforts on strengthening its Diagnostic division. Roche currently carries a Zacks Rank #3 (Hold). Some better-ranked health care stocks are Gilead Sciences Inc. GILD and Valeant Pharmaceuticals International, Inc. VRX. Both carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
VALEANT PHARMA (VRX): Free Stock Analysis Report
ASTELLAS PHARMA (ALPMY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
